Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7194485 | 0.88 | MAPT (0.36) | F2MAPTALDH1A1TGFBR1LMNA | |
| SCHEMBL7196567 | 0.87 | F2 (0.38) | F2MAPTALDH1A1TGFBR1LMNA | |
| SCHEMBL7190513 | 0.86 | F2 (0.41) | F2MAPTALDH1A1TGFBR1PKM | |
| SCHEMBL7187086 | 0.86 | F2 (0.37) | F2MAPTALDH1A1TGFBR1PKM | |
| SCHEMBL3838833 | 0.85 | F2 (0.34) | F2MAPTALDH1A1TGFBR1PKM | |
| SCHEMBL7190085 | 0.80 | F2 (0.36) | F2MAPTALDH1A1TGFBR1PKM | |
| SCHEMBL7189141 | 0.80 | ALDH1A1 (0.40) | MAPTALDH1A1PKMLMNATP53 | |
| SCHEMBL7197225 | 0.79 | MAPT (0.38) | F2MAPTALDH1A1PKMLMNA | |
| SCHEMBL7781107 | 0.76 | ALDH1A1 (0.55) | MAPTALDH1A1PKMLMNAMAPK1 | |
| SCHEMBL3838832 | 0.73 | F2 (0.35) | F2MAPTALDH1A1TGFBR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589972-B2 | Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-08 | — | — | US | disclosed |
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | SCHOOP ANDREAS (DE) | 2001-10-18 | — | — | US | disclosed |
| US-6291503-B1 | β-phenylalanine derivatives as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | ITGB4, ITGA4, ITGB2 | F2 1860/4885MAPT 3865/4885ALDH1A1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.